Robert McKean - Mineralys Therapeutics Senior CMC
| MLYS Stock | 14.17 0.42 3.05% |
Executive
Robert McKean is Senior CMC of Mineralys Therapeutics Common
| Address | 150 N. Radnor Chester Rd., Radnor, PA, United States, 19087 |
| Phone | 888 378 6240 |
| Web | https://mineralystx.com |
Mineralys Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2891) % which means that it has lost $0.2891 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4138) %, meaning that it created substantial loss on money invested by shareholders. Mineralys Therapeutics' management efficiency ratios could be used to measure how well Mineralys Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.3 in 2024. Return On Capital Employed is likely to drop to -0.37 in 2024. At this time, Mineralys Therapeutics' Total Assets are comparatively stable compared to the past year. Other Current Assets is likely to gain to about 13.2 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 1.9 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Cathleen DeGenova | Avis Budget Group | 62 | |
| Zach Taylor | BioNTech SE | N/A | |
| Jason Arnold | Air Lease | N/A | |
| Katalin Kariko | BioNTech SE | N/A | |
| Oliver Henning | BioNTech SE | N/A | |
| Sebastian MD | BioNTech SE | N/A | |
| David Beker | Air Lease | N/A | |
| Daniel Steiner | Molecular Partners AG | N/A | |
| Eric Hoogenkamp | Air Lease | N/A | |
| Jeff Hoover | Alta Equipment Group | N/A | |
| Renate Gloggner | Molecular Partners AG | 54 | |
| Stephen Wright | Avis Budget Group | N/A | |
| Brian Choi | Avis Budget Group | 41 | |
| Sylke Maas | BioNTech SE | N/A | |
| Siegbert Kloos | BioNTech SE | N/A | |
| Ravindra Simhambhatla | Avis Budget Group | 55 | |
| Jeffrey Chastain | HE Equipment Services | N/A | |
| Sara Evans | Air Lease | N/A | |
| James Ryan | BioNTech SE | 49 | |
| Robert Hendriks | Molecular Partners AG | N/A | |
| Sabrina CPA | Air Lease | N/A | |
Management Performance
| Return On Equity | -0.41 | ||||
| Return On Asset | -0.29 |
Mineralys Therapeutics Leadership Team
Elected by the shareholders, the Mineralys Therapeutics' board of directors comprises two types of representatives: Mineralys Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mineralys. The board's role is to monitor Mineralys Therapeutics' management team and ensure that shareholders' interests are well served. Mineralys Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mineralys Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert McKean, Senior CMC | ||
| Adam Levy, CFO Secretary | ||
| Sarah Foster, Vice Resources | ||
| Danielle Bradbury, Senior Assurance | ||
| Jon Congleton, CEO Director | ||
| Cindy Berejikian, Executive Operations | ||
| Minji MBA, Chief Officer | ||
| Jessica Ibbitson, Senior Operations | ||
| Jeffrey Fellows, Senior Affairs | ||
| David MD, Chief Officer | ||
| MD MPH, Founder Chairman |
Mineralys Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Mineralys Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.41 | ||||
| Return On Asset | -0.29 | ||||
| Current Valuation | 445.86 M | ||||
| Shares Outstanding | 49.63 M | ||||
| Shares Owned By Insiders | 2.95 % | ||||
| Shares Owned By Institutions | 92.44 % | ||||
| Number Of Shares Shorted | 872.86 K | ||||
| Price To Book | 2.67 X | ||||
| EBITDA | (84.66 M) | ||||
| Net Income | (71.9 M) |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Mineralys Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Mineralys Therapeutics' short interest history, or implied volatility extrapolated from Mineralys Therapeutics options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mineralys Therapeutics Common. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Complementary Tools for Mineralys Stock analysis
When running Mineralys Therapeutics' price analysis, check to measure Mineralys Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mineralys Therapeutics is operating at the current time. Most of Mineralys Therapeutics' value examination focuses on studying past and present price action to predict the probability of Mineralys Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mineralys Therapeutics' price. Additionally, you may evaluate how the addition of Mineralys Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |
Is Mineralys Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mineralys Therapeutics. If investors know Mineralys will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mineralys Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.99) | Return On Assets (0.29) | Return On Equity (0.41) |
The market value of Mineralys Therapeutics is measured differently than its book value, which is the value of Mineralys that is recorded on the company's balance sheet. Investors also form their own opinion of Mineralys Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Mineralys Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mineralys Therapeutics' market value can be influenced by many factors that don't directly affect Mineralys Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mineralys Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Mineralys Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mineralys Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.